Abstract: Approaches for the translation of structured text include an embedding module for encoding and embedding source text in a first language, an encoder for encoding output of the embedding module, a decoder for iteratively decoding output of the encoder based on generated tokens in translated text from previous iterations, a beam module for constraining output of the decoder with respect to possible embedded tags to include in the translated text for a current iteration using a beam search, and a layer for selecting a token to be included in the translated text for the current iteration. The translated text is in a second language different from the first language. In some embodiments, the approach further includes scoring and pointer modules for selecting the token based on the output of the beam module or copied from the source text or reference text from a training pair best matching the source text.

Abstract: Approaches for the translation of structured text include an embedding module for encoding and embedding source text in a first language, an encoder for encoding output of the embedding module, a decoder for iteratively decoding output of the encoder based on generated tokens in translated text from previous iterations, a beam module for constraining output of the decoder with respect to possible embedded tags to include in the translated text for a current iteration using a beam search, and a layer for selecting a token to be included in the translated text for the current iteration. The translated text is in a second language different from the first language. In some embodiments, the approach further includes scoring and pointer modules for selecting the token based on the output of the beam module or copied from the source text or reference text from a training pair best matching the source text.

Abstract: Approaches for the translation of structured text include an embedding module for encoding and embedding source text in a first language, an encoder for encoding output of the embedding module, a decoder for iteratively decoding output of the encoder based on generated tokens in translated text from previous iterations, a beam module for constraining output of the decoder with respect to possible embedded tags to include in the translated text for a current iteration using a beam search, and a layer for selecting a token to be included in the translated text for the current iteration. The translated text is in a second language different from the first language. In some embodiments, the approach further includes scoring and pointer modules for selecting the token based on the output of the beam module or copied from the source text or reference text from a training pair best matching the source text.

Abstract: Approaches for the translation of structured text include an embedding module for encoding and embedding source text in a first language, an encoder for encoding output of the embedding module, a decoder for iteratively decoding output of the encoder based on generated tokens in translated text from previous iterations, a beam module for constraining output of the decoder with respect to possible embedded tags to include in the translated text for a current iteration using a beam search, and a layer for selecting a token to be included in the translated text for the current iteration. The translated text is in a second language different from the first language. In some embodiments, the approach further includes scoring and pointer modules for selecting the token based on the output of the beam module or copied from the source text or reference text from a training pair best matching the source text.

Abstract: The present invention relates to thiazolinones and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-?-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.

Abstract: The present invention relates to furanopyrimidine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.